ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study

- ViiV Healthcare presents data indicating that Cabenuva, a long-acting injectable HIV treatment combining Cabotegravir and Rilpivirine, demonstrated superior efficacy compared to daily oral standard of care (SOC).
- The Phase III LATITUDE study revealed that Cabenuva is preferable to daily oral regimens for individuals with adherence challenges.
- An independent data monitoring panel halted randomization and gave participants in the SOC arm the opportunity to switch to Cabenuva due to its superiority.
- Adherence to daily antiretroviral therapy (ART) is crucial for managing HIV, yet it poses challenges; long-acting therapies aim to improve adherence and reduce stigmas associated with daily pill-taking.
- Cabenuva offers advantages such as reduced stigma, convenience, and improved adherence, as 90% of participants who switched to Cabenuva preferred it over daily oral pill Biktarvy.
- Cabenuva was found to be non-inferior to Biktarvy, with 83% and 61% of participants citing convenience and reduction of HIV status thoughts as reasons for preference.

New Titles:
"ViiV's Long-Acting Cabenuva Surpasses Traditional Daily Oral HIV Treatment in Phase III LATITUDE Study"

"Clinical Trial Reveals Superiority of Long-Acting Cabenuva Over Daily Oral Standard of Care for HIV Management"